RituximabSerum sickness following off-label use: 5 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1776卷 / 1期

关键词：

D O I：

10.1007/s40278-019-70556-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：398 / 398

相关论文

共 50 条

[31] Niraparib/romiplostimThrombocytopenia and off-label use: 5 case reports
Reactions Weekly, 2023, 1958 (1) : 411 - 411
[32] RituximabVarious toxicities and off-label use: 5 case reports
Reactions Weekly, 2023, 1952 (1) : 306 - 306
[33] RituximabUrticaria and serum sickness disease following off-label use: case report
Reactions Weekly, 2019, 1776 (1) : 399 - 399
[34] BupivacaineKnee chondrolysis following off-label use: 21 case reports
Reactions Weekly, 2022, 1912 (1) : 127 - 127
[35] DasatinibVarious toxicities following off-label use: 3 case reports
Reactions Weekly, 2021, 1881 (1) : 92 - 92
[36] EltrombopagLack of efficacy following off-label use: 2 case reports
Reactions Weekly, 2025, 2042 (1) : 174 - 174
[37] RituximabVarious toxicities following an off-label use: 3 case reports
Reactions Weekly, 2018, 1683 (1) : 600 - 600
[38] IvermectinVarious toxicities following off-label use: 7 case reports
Reactions Weekly, 2022, 1919 (1) : 335 - 335
[39] PazopanibVarious toxicities following off-label use: 3 case reports
Reactions Weekly, 2023, 1939 (1) : 375 - 375
[40] SorafenibLack of efficacy following off-label use: 2 case reports
Reactions Weekly, 2023, 1940 (1) : 384 - 384

← 1 2 3 4 5 →